Pancreatic disease: Recent advances

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 1, 1999, Pages 33-36

  Sutton, Robert ^a   Slavin, John P ^a   Ghaneh, Paula ^a   Neoptolemos, John P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEXIPAFANT;

ACUTE PANCREATITIS; GENETIC PREDISPOSITION; HUMAN; PANCREAS CANCER; PANCREAS DISEASE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0032974790     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199901000-00007     Document Type: Short Survey

References (57)

1. De Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis: an analysis of 279 cases. Guf 1995; 37:121-126.
2. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998; 175:76-83.
3. Kemppainen EA, Hedstrom J, Puolakkainen P, Halttunen J, Sainio V, Haapainen R, et al. Increased serum trypsinogen 2 and trypsin 2-alpha-1-antitrypsin complex values identify endoscopic cholangiopancreatography induced pancreatitis with high accuracy. Gut 1997; 41:690-695.
4. Gudgeon M, Heath D, Hurley P, Jehanli A, Patel G, Wilson C, et al. Trypsinogen activation peptide assay in the early prediction of severity of acute pancreatitis. Lancet 1990; 335:4-8.
5. Schmidt J, Fernandez-del Castillo C, Rattner DW, Lewandrowski K, Compton CG, Warshaw AL. Trypsinogen and activation peptide in experimental rat pancreatitis: prognostic implications and histopathological correlations. Gastroenterology 1992; 103:1009-1016.
6. Neoptolemos JP, Raraty M, Finch M, Sutton R. Acute pancreatitis: the substantial human and financial costs. Gut 1998; 42:886-889.
7. Kemppainen EA, Hedstrom JI, Haapianinen R, Kivisaari L, Kivilaakso E, Puolakkainen P. Early demonstration of necrosis by contrast-enhanced computed tomography can predict outcome in severe acute pancreatitis. Br J Surg 1996; 83:924-929.
8. Bassi C. Infected pancreatic necrosis. Int J Pancreatol 1994; 16:1-10.
9. Sainio V, Kamppainnen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V, et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995; 346:663-667.
10. Mithofer K, Fernandez-del Castillo F, Ferraro MJ, Lewandrowski K, Rattner DW, Warshaw AL. Antibiotic treatment improves survival in experimental acute necrotising pancreatitis. Gastroenterology 1996; 110:232-240.
11. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomised multicentre trial of antibiotic prophylaxis of septic complications in acute necrotising pancreatitis with imipenem. Surg Gynecol Obstet 1993; 176:480-483.
12. Runkel NS, Moddy FG, Smith GS, Rodriguez LF, LaRocco MT, Miller TA. The role of the gut in the development of sepsis in acute pancreatitis. J Surg Res 1991; 51:18-23.
13. Deitch EA, Winterton J, Li M, Berg R. The gut as a portal of entry for bacteraemia. Role of protein malnutrition. Ann Surg 1987; 205:681-692.
14. Kalfarentzos F, Kegagias J, Mead N, Kokkinis K, Gogos CA. Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomised prospective trial. Br J Surg 1997; 84:1665-1669.
15. Windsor AC, Kanwar S, Li AK. Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis. Gut 1998; 42:431-435.
16. Neoptolemos JP. The theory of persisting common bile duct stones in severe gallstones pancreatitis. Ann R Coll Surg Engl 1989; 71:326-331.
17. Neoptolemos JP, Carr-Locke DL, London NJ, Bailey IA, James D, Fossara DP. Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones. Lancet 1988; ii:979-983.
18. Fan ST, Lai EC, Mok FP, Lo CM, Zheng SS, Wong J. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. N Engl J Med 1993; 328:228-232.
19. Nowak A, Nowakowska-Dulawa E, Marek TA, Rybicka J. Final results of the prospective, randomized, controlled study on endoscopic sphincterotomy versus conventional management in acute biliary pancreatitis [abstract]. Gastroenterology 1995; 108:A380.
20. Fölsch UR, Nitsche R, Ludtke R, Hilgers RA, Creutzfeldt W. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. N Engl J Med 1997; 336:237-242.
21. Sinclair MT, McCarthy A, McKay C, Sharpies CE, Imrie CW. The increasing incidence and high mortality rate from acute pancreatitis in Scotland over the last ten years [abstract]. Gastroenterology 1997; 112(suppl 4):A482.
22. Steer ML, Meldolesi J. Pathogenesis of acute pancreatitis. Annu Rev Med 1988; 39:95-105.
23. Otani T, Atomi Y, Kuroda A, Muto T, Tamura M, Fukuda S. Distribution of a synthetic protease inhibitor in rat pancreatic acini after supramaximal secretagogue stimulation. Pancreas 1997; 14:142-149.
24. Leach SD, Modlin IM, Scheele GA, Gorelick FS. Intracellular activation of digestive zymogens in rat pancreatic acini. Stimulation by high doses of CCK. J Clin Invest 1991; 87:362-366.
25. Hofbauer B, Saluja AK, Lerch MM, Bhagat L, Bhatia M, Lee HS, et al. Intraacinar cell activation of trypsinogen during caerulein induced pancreatitis in rats. Am J Physiol 1998; 275:G352-G362.
26. Ward JB, Sutton R, Petersen OH. Ethanol interacts with the CCK receptor and causes calcium release from intracellular pools in mouse pancreatic acinar cells [abstract]. Br J Surg 1996; 83:1632.
27. Ward JB, Petersen OH, Jenkins SA, Sutton R. Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Lancet 1995; 346:1016-1019.
28. Fink G, Yang J, Carter G, Norman J. Acute pancreatitis-induced enzyme release and necrosis are attenuated by IL-1 antagonism through an indirect mechanism. J Surg Res 1997; 67:94-97.
29. Tanaka N, Murata A, Uda K, Toda H, Kato T, Hayashida H, et al. Interleukin-I receptor antagonist modifies the changes in vital organs induced by acute necrotising pancreatitis in a rat experimental model. Crit Care Med 1995; 23:901-908.
30. Denham W, Fink G, Yang J, Ulrich P, Tracey K, Norman J. Small molecule inhibition of tumor necrosis factor gene processing during acute pancreatitis prevents cytokine cascade progression and attenuates pancreatitis severity. Am Surg 1997; 63:1045-1049, discussion 1049-1050.
31. Norman JG, Fink GW, Messina J, Carter G, Franz MG. Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. Surgery 1996; 120:515-521.
32. Grewal HP, el-Din AM, Gaber L, Kotb M, Gaber AO. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am J Surg 1994; 167:214-218, discussion 218-219.
33. Dabrowski A, Gabryelewicz A, Chyczewski L. The effect of platelet activating factor antagonist (BN 52021) on acute experimental pancreatitis with reference to multiorgan oxidative stress. Int J Pancreatol 1995; 17:173-180.
34. Galloway SW, Kingsnorth AN. Lung injury in the microembolic model of acute pancreatitis and amelioration by lexipafant (BB-882), a platelet-activating factor antagonist. Pancreas 1996; 13:140-146.
35. Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human pancreatitis. Br J Surg 1995; 82:1414-1420.
36. Kingsnorth AN. Early treatment with lexipafant, a platelet activating factor antagonist reduces mortality in acute pancreatitis: a double blind, randomised, placebo controlled study [abstract]. Gastroenterology 1997; 112:A453.
37. Comfort M, Steinberg A. A pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952; 21:54-63.
38. Lowenfels AB, Maisonneuve P, DiMango EP, Elitsur Y, Gates Jr LK, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997; 89:442-446.
39. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genetics 1996; 14:141-145.
40. Gorry MC, Gabbaizedeh D, Furey W, Gates Jr LK, Preston RA, Aston CE, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology 1997; 113:1063-1068.
41. Howes N, Rutherford S, McRonald F, Ellis I, Whitcomb D, Mountford R, Neoptolemos JP. Trypsinogen mutations in families with hereditary pancreatitis in the UK and Ireland [abstract]. Digestion 1998; 59:204.
42. Lowenfels AB, Maisonneuve P, Cavallini G, Amman RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433-1437.
43. Neoptolemos JP, Russell RCG, Bramhall S. Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. Br J Surg 1997; 84:1370-1376.
44. Conlon KC, Klimstra DS, Brennan MF. Long term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5 year survivors. Ann Surg 1996; 223:273-279.
45. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Incidence, treatment and survival in 13,560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1995; 82:111-115.
46. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992; 102:230-236.
47. Barton CM, Staddo SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, et al. Abnormalities of the tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64:1076-1082.
48. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W. Frequent codeletion of p16 and genetic alterations in p16 in pancreatic tumours. Gastroenterology 1996; 110:1215-1224.
49. Hahn SA, Hoque ATMS, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996; 56:490-494.
50. McCarthy MJ, Evans JD, Sagar G, Neoptolemos JP. Prediction of resectability of pancreatic malignancy by computed tomography. Br J Surg 1998; 85:320-325.
51. John TG, Greig JD, Carter DC, Garden OJ. Carcinoma of the pancreatic head and peri-ampullary region. Tumour staging with laparoscopy and laparoscopic ultrasonography. Ann Surg 1995; 221:156-164.
52. Pederzoli P, Bassi C, Falconi M, Pedrazzoli S. Does the extent of lymphatic resection affect the outcome in pancreatic cancer? Digestion 1997; 58:536-541.
53. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomised trial. J Clin Oncol 1997; 15:2403-2413.
54. Carmichael J, Lederman JA, Woll PJ, Gulliford T, Russell RC. A phase Ib study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17:232A.
55. Ghaneh P, Humphreys M, Greenhalf W, Lemoine N, Neoptolemos JP. Effects of p53 and p16 transfer in pancreatic cancer cells [abstract]. Br J Cancer 1998; 78:19.
56. Klinkenbijl J, Sahmoud T, Van Pei R, Couvreur ML, Veenhof CHN, Arnaud TP, et al. Radiotherapy and 5-fluorouracil after curative resection for cancer of the pancreas and periampullary region. A phase III trial of the EORTC GITCCG [abstract]. Eur J Cancer 1997; 33:1239.
57. Neoptolemos JP, Kerr DJ, Beger H, Link K, Pederzoli P, Bassi C, et al. ESPAC-1 trial progress report: the European randomised adjuvant study comparing chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion 1997; 58:570-577.